Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.

ABSTRACT:

SUBMITTER:  

PROVIDER: S-EPMC6456793 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature